In various aspects, the invention provides for the humanization of the ratanti-beta7integrin subunit monoclonal antibody FIB504, inhibition by such humanizedantibodies of the binding of beta7 subunit-containing integrins to theirligands, anduse of such antibodies in the treatment of certain disorders including, forexample,inflammatory bowel disease, Crohn's disease, ulcerative colitis and otherinflammatory disorders.